Has the CSL share price got further to fall?

ASX experts weigh in on what's next for CSL.

| More on:
Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Well, things were looking up for the CSL Ltd (ASX: CSL) share price. Until 12 February earlier this month, that is. 

Between late October and 12 February, CSL shares were on a tear. This ASX 200 healthcare stock rose more than 32% between those two dates. But after the company released some bitterly disappointing test results for a new cardiovascular drug, investors lost a lot of their confidence.

Since 12 February, CSL shares have tanked by more than 6.6%, falling from over $300 each to the $285.50 we see today (at market close).

Not even a confident earnings report earlier this month could restore investor enthusiasm. As we covered at the time, those earnings revealed that CSL was able to record an 11% rise in revenues, as well as a 20% increase in net profits for the six months ending 31 December. Investors were also treated to a 12% dividend pay rise.

Check out the CSL share price's movements below for yourself:

So with CSL shares coming off the boil and seemingly not getting back on, ASX investors might be asking themselves whether CSL shares have further to fall. After all, it was only in late October that this healthcare giant got as low as $228.65 a share.

Does the CSL share price have further to fall?

Well, let's see what some ASX experts think.

Following the release of CSL's earnings, my Fool colleague James covered the views of ASX broker Morgans. Morgans did trim its price target for CSL shares following its disappointing trial results. But it still rates the company as an add following its earnings, with a price target of $315.40. If realised, that would represent an upside of more than 10% from current prices.

Morgans was happy with what CSL reported earlier this month and evidently sees significant value in the company's share price at its current levels.

But Morgans isn't the only expert that is eyeing off the healthcare giant right now. eToro analyst Josh Gilbert shares a positive view. Here's some of what he recently said about CSL right now:

CSL shareholders will have reason to smile today with the release of a solid half-yearly report… [These] results show that the business continues to move in the right direction, and there is plenty to be positive about. With solid profit growth, a healthy dividend, solid guidance, and interest rate cuts not far away, CSL will be on investors' watchlists.

So it appears that at least two ASX experts reckon CSL shares are more likely to head up than down going forward. But, as always, we'll have to wait and see if that turns out to be the case.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Healthcare Shares

Why are so many top fundies overweight on CSL shares?

This is a healthy opportunity, according to a number of fund managers.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Share Fallers

Why did this ASX All Ords stock just crash 16%?

Investors are punishing this ASX All Ords stock on Thursday. But why?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Healthcare Shares

Why two brokers have named this ASX 200 stock as a best buy

Investors may want to pounce on this high-quality stock before it's too late.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

What could $5,000 invested in CSL shares become in 1 year?

Let's see what sort of returns analysts are tipping for this ASX giant.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is everyone talking about Mesoblast shares?

ASX biotech share Mesoblast has been grabbing plenty of investor attention recently.

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Why the Mesoblast share price can rise another 60%

The big gains may not be over according to Bell Potter.

Read more »